8VYE

SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs

これはPDB形式変換不可エントリーです。

8VYE の概要

• エントリーDOI: 10.2210/pdb8vye/pdb
• 関連するPDBエントリー: 8VYF 8VYG
• EMDBエントリー: 43658
• 分子名称: Spike glycoprotein, S2L20 Heavy Chain, S2L20 Light Chain, ... (8 entities in total)
• 機能のキーワード: sars-cov-2, coronavirus, lambda, s309, s2l20, s2x303, c.37, antibody, fab, s protein, spike, fusion protein, structural genomics, seattle structural genomics center for infectious disease, ssgcid, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 21
• 化学式量合計: 662493.98

構造登録者

McCallum, M.,Veesler, D.,Seattle Structural Genomics Center for Infectious Disease (SSGCID) (登録日: 2024-02-08, 公開日: 2024-03-27)

主引用文献

Magaret, C.A.,Li, L.,deCamp, A.C.,Rolland, M.,Juraska, M.,Williamson, B.D.,Ludwig, J.,Molitor, C.,Benkeser, D.,Luedtke, A.,Simpkins, B.,Heng, F.,Sun, Y.,Carpp, L.N.,Bai, H.,Dearlove, B.L.,Giorgi, E.E.,Jongeneelen, M.,Brandenburg, B.,McCallum, M.,Bowen, J.E.,Veesler, D.,Sadoff, J.,Gray, G.E.,Roels, S.,Vandebosch, A.,Stieh, D.J.,Le Gars, M.,Vingerhoets, J.,Grinsztejn, B.,Goepfert, P.A.,de Sousa, L.P.,Silva, M.S.T.,Casapia, M.,Losso, M.H.,Little, S.J.,Gaur, A.,Bekker, L.G.,Garrett, N.,Truyers, C.,Van Dromme, I.,Swann, E.,Marovich, M.A.,Follmann, D.,Neuzil, K.M.,Corey, L.,Greninger, A.L.,Roychoudhury, P.,Hyrien, O.,Gilbert, P.B.
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Nat Commun, 15:2175-2175, 2024

PubMed Abstract: In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p < 0.05]. VE differed by residue match vs. mismatch to the vaccine-insert at 16 amino acid positions (4 FWER p < 0.05; 12 q-value ≤ 0.20); significantly decreased with physicochemical-weighted Hamming distance to the vaccine-strain sequence for Spike, receptor-binding domain, N-terminal domain, and S1 (FWER p < 0.001); differed (FWER ≤ 0.05) by distance to the vaccine strain measured by 9 antibody-epitope escape scores and 4 NTD neutralization-impacting features; and decreased (p = 0.011) with neutralization resistance level to vaccinee sera. VE against severe-critical COVID-19 was stable across most sequence features but lower against the most distant viruses.

PubMed: 38467646
DOI: 10.1038/s41467-024-46536-w

実験手法

ELECTRON MICROSCOPY (2.7 Å)